Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Objective To clarify the impact of digoxin on death and clinical outcomes across all
observational and randomised controlled trials, accounting for study designs and methods …

Background Mineralocorticoid-receptor antagonists improve the prognosis for patients with
heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of …

Importance Diastolic heart failure (ie, heart failure with preserved ejection fraction) is a
common condition without established therapy, and aldosterone stimulation may contribute …

Aims Many patients who receive a diagnosis of heart failure have neither a low left
ventricular (LV) ejection fraction nor valve disease. Few substantial randomized controlled …

ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Control of the heart rate (rate control) is central to atrial fibrillation management, even for
patients who ultimately require control of the rhythm. We review heart rate control in patients …

Heart failure resulting in hospitalization represents a significant and growing health care
burden. Heterogeneity characterizes this group in terms of mode of presentation …

Background—About half of the 5 million heart failure patients in the United States have
diastolic heart failure (clinical heart failure with normal or near-normal ejection fraction) …

Aims Digoxin is frequently used for rate control of atrial fibrillation (AF). It has, however, been
associated with increased mortality. It remains unclear whether digoxin itself is responsible …